News

Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical. Abilify ODT, which utilizes Catalent's Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated...

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots...

  The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets* (approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago) for the...

AstraZeneca announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. PAD patients are...

GlaxoSmithKline plc and Human Genome Sciences have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity...

GlaxoSmithKline plc (GSK) and Theravance, Inc. announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a...

In future patients with certain diseases, especially chronic ones, should be treated in a more holistic approach beyond drug treatment only. Thus Boehringer Ingelheim is concentrating on new business models and healthcare innovation and...